Home World News FDA Approves Durvalumab for Muscle Invasive Bladder Cancer World News FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 904 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... September 24, 2024 Severe Side Effects of Cancer Treatment Are More Common in Women... March 15, 2022 EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of... November 19, 2024 Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... September 13, 2024 Load more HOT NEWS COVID-19: “We’re having to rebuild and adapt because of coronavirus” What Are Clinical Practice Guidelines and How Do They Impact Care... How to Tell If Cancer Information on Social Media Is “Fake... Cancer in My Community: Accessing Care Through the Public Health System...
